OVERSEA CHINESE BANKING Corp Ltd Takes $6.71 Million Position in Illumina, Inc. $ILMN

Posted by George Bondi on Aug 21st, 2026

OVERSEA CHINESE BANKING Corp Ltd bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 38,167 shares of the life sciences company’s stock, valued at approximately $6,711,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ILMN. Capital World Investors raised its holdings in shares of Illumina by 0.6% during the fourth quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock valued at $2,636,483,000 after acquiring an additional 124,323 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of Illumina in the second quarter worth approximately $3,374,423,000. State Street Corp boosted its stake in shares of Illumina by 3.2% in the fourth quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock worth $811,895,000 after acquiring an additional 190,324 shares during the last quarter. WCM Investment Management LLC increased its position in shares of Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares in the last quarter. Finally, AQR Capital Management LLC increased its position in shares of Illumina by 30.3% during the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after purchasing an additional 1,028,099 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Illumina news, CAO Scott D. Ericksen sold 500 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $160.00, for a total value of $80,000.00. Following the completion of the sale, the chief accounting officer directly owned 14,446 shares of the company’s stock, valued at $2,311,360. This trade represents a 3.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the transaction, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,416,384 shares of company stock worth $256,164,151. 2.90% of the stock is currently owned by company insiders.

Illumina Price Performance

ILMN stock opened at $213.24 on Friday. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $220.32. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The firm has a market capitalization of $32.20 billion, a PE ratio of 39.78, a price-to-earnings-growth ratio of 2.89 and a beta of 1.45. The business has a 50 day simple moving average of $186.84 and a 200-day simple moving average of $151.97.

Illumina (NASDAQ:ILMN – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm’s revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on ILMN. Sanford C. Bernstein restated a “market perform” rating and issued a $215.00 price objective on shares of Illumina in a report on Friday, July 31st. Stifel Nicolaus upped their target price on shares of Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Zacks Research raised shares of Illumina from a “hold” rating to a “strong-buy” rating in a report on Monday, August 3rd. Citigroup increased their target price on shares of Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research report on Monday, August 3rd. Finally, Guggenheim raised their price target on shares of Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Illumina currently has a consensus rating of “Hold” and an average price target of $188.40.

View Our Latest Analysis on ILMN

Illumina Profile

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.